TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29284320
Drug: Inhaled laninamivir
Normalized name: laninamivir
DrugBank: Laninamivir (DB12791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled laninamivir
Study: 23877621
Drug: Warfarin maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin maintenance dosing algorithm
Study: 9894360
Drug: Retinyl propionate
Normalized name: Retinyl Propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl propionate cream
Study: 2653717
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime (CTX) 200 mg/kg/day
Study: 27324833
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of instructor and device feedback (IDFB)
Study: 21824799
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day of conjugated equine estrogens
Study: 30797386
Drug: Alcohol Behavioral
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol Behavioral Couple Therapy (ABCT)
Study: 19309184
Drug: Alcohol Behavioral
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol Behavioral Individual Therapy (ABIT)
Study: 16886978
Drug: Rufinamide 200
Normalized name: rufinamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufinamide 200 mg/day
Study: 16886978
Drug: Rufinamide 400
Normalized name: rufinamide 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufinamide 400 mg/day
Study: 16886978
Drug: Rufinamide 800
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rufinamide 800 mg/day
Study: 16886978
Drug: Rufinamide 1600
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rufinamide 1600 mg/day
Study: 15260911
Drug: rilmenidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine 3 mg once daily
Study: 7895460
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Glibenclamide (MGL)
Study: 7895460
Drug: Monotherapy (Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (Metformin or Glibenclamide)
Study: 7895460
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Metformin and Glibenclamide)
Study: 2441013
Drug: Monthly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group sessions with videotapes for diabetic persons with low literacy skills
Study: 2441013
Drug: Monthly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group sessions without videotapes
Study: 2441013
Drug: No monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: No monthly sessions
Study: 19077067
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management with medium chain triglyceride-enriched diet or total parenteral nutrition in combination with adequate drainage of pleural fluid
Study: 19077067
Drug: Somatostatin or
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin or octreotide therapy
Study: 10528370
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human bone morphogenetic protein 2 treatment groups
Study: 2139285
Drug: Recombinant yeast-derived
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant yeast-derived hepatitis B vaccine (YDV) 20 micrograms, administered according to a 0, 1, 6 month schedule.
Study: 507790
Drug: Ideal body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ideal body weight for AMG dosage calculation
Study: 21323524
Drug: pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegfilgrastim 6 mg on day +1
Study: 21323524
Drug: filgrastim (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: filgrastim (daily starting at median day +7)
Study: 19369086
Drug: Lisinopril (postoperatively)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (postoperatively)
Study: 19369086
Drug: No angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No angiotensin converting enzyme inhibitor (control group)
Study: 16496034
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment (adherent)
Study: 8182270
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of 25 units iHAV i.m. given 1 or 2 months after primary immunization
Study: 8182270
Drug: 0.06 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 ml/kg IG i.m. given once
Study: 29703262
Drug: Migalastat 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migalastat 150 mg every other day
Study: 27107523
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of hyperbaric bupivacaine 0.25% plus 1mL of sufentanil
Study: 27107523
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of hyperbaric bupivacaine 0.25% plus 1mL of placebo
Study: 22078217
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) group treatment
Study: 20729016
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (500 mL/d) with aerobic training (1h, 3 times a week for 3 months)
Study: 9182022
Drug: FAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC plus dexrazoxane (administered after six courses of FAC)
Study: 8314510
Drug: Steroids (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (1 mg/kg/day of prednisone)
Study: 30958316
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (BMT), n=20
Study: 30028478
Drug: Subcostal TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcostal TAP block in addition to intravenous analgesic regimen (group II)
Study: 30028478
Drug: Intravenous analgesic
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesic regimen alone (group I)
Study: 27480203
Drug: Nurse-initiated protocol
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nurse-initiated protocol for acetaminophen administration for patients with pain or fever
Study: 23227682
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Shu‐stream and Ying‐spring acupoints (group A)
Study: 18922041
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of vitamin K1 daily
Study: 15838417
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of the Stroke Impact Scale (SIS)
Study: 15838417
Drug: Mail administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mail administration of the Stroke Impact Scale (SIS)
Study: 14503058
Drug: Dandi Tablet
Normalized name: Titanium Dioxide 0.18 g in 4.5 g TOPICAL LIPSTICK [3CE CRE AMY LIP COLOR 08 LADI DADI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dandi Tablet (DDT), 4 tablets twice a day for 3 months
Study: 14503058
Drug: Nylestriol, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylestriol, 5 mg every month for 3 months
Study: 10936116
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 microg once daily
Study: 10903487
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 microg once daily
Study: 10903487
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 microg once daily
Study: 27764799
Drug: Polymeric nanoparticle
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 75 mg/m2
Study: 27764799
Drug: Polymeric nanoparticle
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 60 mg/m2
Study: 27764799
Drug: Polymeric nanoparticle
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 45 mg/m2
Study: 27764799
Drug: Docetaxel (DTX)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (DTX) at 75 mg/m2
Study: 20422942
Drug: New donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: New donepezil 10 mg formulation (test formulation)
Study: 16724375
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program for general practitioners on pain management (relationships and communication, pain evaluation, prescription, negotiation of a patient contract)
Study: 8649620
Drug: Low-dose desferrioxamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose desferrioxamine (DFO) 5 mg/kg administered 5 hours prior to dialysis (group I: n = 14)
Study: 8649620
Drug: Low-dose desferrioxamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose desferrioxamine (DFO) 5 mg/kg administered in the conventional way (group II: n = 27)
Study: 8649620
Drug: Low-dose desferrioxamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose desferrioxamine (DFO) treatment
Study: 1462278
Drug: Anti-inflammatory complex
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory complex therapy with Mydocalm
Study: 1462278
Drug: Anti-inflammatory complex
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory complex therapy (control)
Study: 6723838
Drug: N-acetylcysteine in
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine in combination with inhaled terbutaline
Study: 23849625
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate plus formoterol (FL/F) 250/12 μg b.i.d. via dry powder inhaler (DPI)
Study: 23849625
Drug: Budesonide plus
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide plus formoterol (BD/F) 400/12 μg b.i.d.
Study: 22052266
Drug: Small gel-particle
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small gel-particle hyaluronic acid (SGP-HA)
Study: 22052266
Drug: Large gel-particle
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large gel-particle hyaluronic acid (LGP-HA)
Study: 16495194
Drug: Thymosin alpha(1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha(1) 11.6 mg subcutaneously daily for 7 days
Study: 16495194
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 ml daily for 7 days (Control)
Study: 11386491
Drug: naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone 50 mg/day
Study: 11386491
Drug: naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone 50 mg/day with cognitive coping skills
Study: 9243422
Drug: Physical fitness
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical fitness program as an adjunct to the usual program
Study: 9243422
Drug: Physical fitness
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical fitness program with therapy
Study: 8474059
Drug: Gold therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold therapy (early treatment)
Study: 8474059
Drug: Delayed gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed gold therapy (treatment after 6 months)
Study: 31600221
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene Blue (MB) with Artesunate-Amodiaquine (AS-AQ) (15 mg/kg/day for 3 days)
Study: 31600221
Drug: Primaquine (PQ)
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine (PQ) with Artesunate-Amodiaquine (AS-AQ) (0.25 mg/kg at day 2)
Study: 28178004
Drug: Combined Jessner
Normalized name: lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Jessner solution and TCA (20%-25%)
Study: 21865364
Drug: Atropine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (15 μg/kg bolus, 4 μg/kg · h infusion)
Study: 21865364
Drug: Physostigmine (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.12 μg/kg · min)
Study: 17109305
Drug: Buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone treatment with brief physician management
Study: 17109305
Drug: Buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone treatment with physician management and nurse-administered drug counseling
Study: 9578185
Drug: Imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10 mg single dose
Study: 9578185
Drug: Imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10 mg steady state (28 days therapy)
Study: 1282183
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg nitroglycerin
Study: 31788775
Drug: Lateral position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral position (L)
Study: 31451978
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) with therapist support
Study: 31451978
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) without therapist support
Study: 25876640
Drug: Sufentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil group (S) - 150 mL normal saline containing 2.5 µg/kg sufentanil citrate and 6 mg tropisetron for 48 hours
Study: 25876640
Drug: Dezocine+sufentanil group
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dezocine+sufentanil group (DS) - 150 mL normal saline containing 0.25 mg/kg dezocine, 1.5 µg/kg sufentanil citrate, and 6 mg tropisetron for 48 hours
Study: 21103921
Drug: Lycopene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (30 mg/day)
Study: 21103921
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3 g/day, including 1,098 mg eicosapentaenoic and 549 mg docosahexaenoic fatty acids)
Study: 31615937
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Abemaciclib + Anastrozole)
Study: 31615937
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Abemaciclib, Anastrozole, Combination)
Study: 27113948
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA (1.95g orally 2 hours preoperatively)
Study: 24690201
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment (clinician controlled), receiving care on a regular basis
Study: 24690201
Drug: Symptom-guided treatment
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-guided treatment (patient controlled), receiving care when patients feel a need
Study: 24690201
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment (clinician controlled)
Study: 24690201
Drug: Symptom-guided treatment
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-guided treatment (patient controlled)
Study: 18607963
Drug: Intratympanic gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gentamicin treatment
Study: 16322468
Drug: Total therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total therapy 2 without thalidomide (TT2)
Study: 12936973
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg single oral dose
Study: 21499876
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment programs (control group)
Study: 20007923
Drug: BIBW 2948
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2948 (15 mg twice a day)
Study: 20007923
Drug: BIBW 2948
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2948 (30 mg twice a day)
Study: 18673350
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and diphenhydramine
Study: 15910627
Drug: Insulin-treated Type
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated Type 2 diabetes
Study: 12632426
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin plus low-dose aspirin
Study: 8785254
Drug: Rifabutin in
Normalized name: Product containing rifabutin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin in combination with isoniazid, ethambutol, and clofazimine
Study: 1718367
Drug: Zinc supplements
Normalized name: Zinc Supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplements (30 mg/d for 3 d)
Study: 22978561
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First intervention (Assertive Community Treatment for high needs participants and Intensive Case Management for moderate needs participants)
Study: 18031315
Drug: Pioglitazone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (7.5 mg/day) added to flutamide (62.5 mg/day) and metformin (850 mg/day)
Study: 15919695
Drug: Daily haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily haemodialysis (DHD) - 2-3 hours, 6 times/week
Study: 11471639
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of etodolac
Study: 9094887
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acid (PUFA) ingestion (low dosage)
Study: 9094887
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acid (PUFA) ingestion (high dosage)
Study: 8104091
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg IV bolus of etilefrine followed by continuous infusion (0.35 mg.kg‐1.h‐1)
Study: 8104091
Drug: 30 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml.kg‐1 infusion of saline isotonic solution for 90 min
Study: 8104091
Drug: No preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preventive treatment (control group)
Study: 2883784
Drug: DTP vaccine,
Normalized name: DTP Vaccine, intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine, initial immunization at five months of age or later, second dose at eight weeks or more
Study: 2883784
Drug: DTP vaccine,
Normalized name: DTP Vaccine, intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine, initial immunization at ages less than five months
Study: 24630820
Drug: Burn rehabilitation
Normalized name: Burn Jel Plus
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Burn rehabilitation massage therapy
Study: 24630820
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation therapy for hypertrophic scars
Study: 22471132
Drug: Tolterodine 1
Normalized name: tolterodine 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 1 mg orally, twice a day + electroacupuncture (Baihui, Sishengcong, Yintang) once a day
Study: 22471132
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg orally, twice a day
Study: 19825835
Drug: Evening administered
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administered bimatoprost/timolol fixed combination (BTFC)
Study: 19825835
Drug: Morning administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administered bimatoprost/timolol fixed combination (BTFC)
Study: 27272076
Drug: Bimatoprost monotherapy
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost monotherapy
Study: 15692986
Drug: Meloxicam 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 0.125 mg/kg body weight (single daily dose)
Study: 15692986
Drug: Meloxicam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 0.25 mg/kg body weight (single daily dose)
Study: 15692986
Drug: Naproxen 10
Normalized name: naproxen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 10 mg/kg body weight (2 daily doses)
Study: 12685513
Drug: Nicardipine 60
Normalized name: niCARdipine 60 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 60 mg/day (titrated to 10 mg/day if necessary)
Study: 10327211
Drug: Cellular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellular and cytokine therapy